News

China Daily3h
Pharmaceutical levies won't prompt reshoring: China Daily editorial
The US initiated a Section 232 investigation on pharmaceutical products in April, purportedly to verify the impact of imports ...
BioSpace11hOpinion
Opinion: How AI Can Help Pharma Companies Adapt to Policy Pressures
The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...
Pharmaceutical industry still in the dark over 200% tariffs
The Canadian pharmaceutical industry is still waiting to learn about tariffs as high as 200 per cent on exports to the U.S.
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...
StockStory.org on MSN3h
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its ...
Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...
The American Bazaar2d
The $400 Billion Patent Cliff: Big Pharma’s Revenue Crisis
President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...
GlobalData on MSN1d
Pharma CEOs downplay impact of tariffs amid rising cost concerns
Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.